These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 15109534

  • 1. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M.
    Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
    [Abstract] [Full Text] [Related]

  • 2. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW, Veal GJ, Radivoyevitch T, Tilby MJ, Meyerson HJ, Lazarus HM, Koc ON, Creger RJ, Pearson G, Nowell GM, Gosky D, Ingalls ST, Hoppel CL, Gerson SL.
    Clin Cancer Res; 2004 Oct 15; 10(20):6830-9. PubMed ID: 15501959
    [Abstract] [Full Text] [Related]

  • 4. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F.
    Ann Hematol; 2009 Feb 15; 88(2):151-8. PubMed ID: 18709502
    [Abstract] [Full Text] [Related]

  • 5. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 15; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 6. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S, Paydas S, Disel U, Sahin B.
    Am J Ther; 2006 Dec 15; 13(5):389-93. PubMed ID: 16988532
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 15; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 8. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A, Polish Adult Leukemia Group.
    Eur J Haematol; 2008 Feb 15; 80(2):115-26. PubMed ID: 18076637
    [Abstract] [Full Text] [Related]

  • 9. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL.
    Am J Hematol; 2008 Mar 15; 83(3):185-8. PubMed ID: 17899614
    [Abstract] [Full Text] [Related]

  • 10. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 15; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 11. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Apr 15; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 12. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Aldoss I, Ji L, Haider M, Pullarkat V.
    Acta Haematol; 2014 Apr 15; 131(4):202-7. PubMed ID: 24296475
    [Abstract] [Full Text] [Related]

  • 13. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    Candoni A, Simeone E, Tiribelli M, Malagola M, Russo D, Fanin R.
    Am J Hematol; 2009 Oct 15; 84(10):690-2. PubMed ID: 19731308
    [No Abstract] [Full Text] [Related]

  • 14. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
    Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, Danise P, Palmieri S.
    Haematologica; 2005 Jun 15; 90(6):776-84. PubMed ID: 15951290
    [Abstract] [Full Text] [Related]

  • 15. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
    Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ.
    Cancer Chemother Pharmacol; 2003 Dec 15; 52(6):449-52. PubMed ID: 13680159
    [Abstract] [Full Text] [Related]

  • 16. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
    Montillo M, Ricci F, Tedeschi A, Cafro AM, Nosari AM, Nichelatti M, Marbello L, Morra E.
    Leuk Res; 2009 Aug 15; 33(8):1072-8. PubMed ID: 19187960
    [Abstract] [Full Text] [Related]

  • 17. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 18. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.
    Ann Hematol; 2014 Dec 15; 93(12):2011-8. PubMed ID: 24989345
    [Abstract] [Full Text] [Related]

  • 19. [Modified FLAG regimen in the management of refractory acute myeloid leukemia].
    Yang LJ, Meng FY, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Xu D, Sun J, Liu QF.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Oct 15; 23(10):1054-5. PubMed ID: 14559692
    [Abstract] [Full Text] [Related]

  • 20. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 15; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.